Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion type Assertion NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_head.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion description "[Our results suggest that PSK may augment anti-tumour action via genes including multidrug resistance protein 3 (MRP3), lymphotactin (Lptn), transgelin (TAGLN), and Pirin, without disturbing cell-cycle progression, and may deserve a large clinical trial in cancer therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion evidence source_evidence_literature NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion SIO_000772 15547752 NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion wasDerivedFrom befree-20140225 NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.
- NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_assertion wasGeneratedBy ECO_0000203 NP348772.RA4dMWf6l-v1xwqkdY2WIVGwG19iMv4EaL2t7OHedDx-c130_provenance.